Article metrics

PDF
SAT0228 Sustained Clinical Benefit with Multiple Courses of Rituximab in Second Line for ALL Rheumatoid Arthtritis Patients Irrespective to the Inhibitor of Tumour Necrosis Factor Previously Used: 3-Year Data from REPEAT Study

Statistics from Altmetric.com

Online download statistics by month:

Online download statistics by month: June 2014 to January 2018

AbstractFullPdf
Jun 2014200
Jul 2014300
Aug 2014702
Sep 2014400
Oct 20141301
Nov 2014700
Dec 2014301
Jan 2015700
Mar 2015201
Apr 2015300
Jun 2015100
Jul 2015300
Aug 2015200
Sep 2015800
Nov 2015401
Dec 2015200
Jan 2016200
Mar 2016701
Apr 2016600
May 2016300
Jun 2016802
Jul 2016900
Aug 2016900
Sep 2016401
Oct 2016700
Nov 20167019
Dec 2016901
Jan 2017601
Feb 2017300
Mar 2017600
Apr 2017802
May 20171000
Jun 2017701
Jul 2017300
Aug 2017500
Sep 20171000
Oct 2017400
Nov 2017400
Dec 20171801
Jan 20181600
Total242035